{{Drugbox
| IUPAC_name = <small>(4a''R'',4b''S'',6a''S'',7''S'',9a''S'',9b''S'',11a''R'')-1,4a,6a-trimethyl-2-oxo-''N''-(propan-2-yl)-''N''-(propan-2-ylcarbamoyl)hexadecahydro-1''H''-indeno[5,4-f]quinoline-7-carboxamide</small>
| image = Turosteride_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Never marketed
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 137099-09-3
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 65986
| ChemSpiderID = 59380
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = LU1LTK666W
| synonyms = <small>1-(4-methyl-3-oxo-4-aza-5-alpha-androstane-17-beta-carbonyl)-1,3- diisopropylurea</small>

<!--Chemical data-->
| C=27 | H=45 | N=3 | O=3 
| molecular_weight = 459.66 g/mol
| smiles = O=C(NC(C)C)N(C(=O)[C@@H]2[C@]1(CC[C@H]3[C@H]([C@@H]1CC2)CC[C@H]4N(C(=O)CC[C@]34C)C)C)C(C)C
| StdInChI=1S/C27H45N3O3/c1-16(2)28-25(33)30(17(3)4)24(32)21-10-9-19-18-8-11-22-27(6,15-13-23(31)29(22)7)20(18)12-14-26(19,21)5/h16-22H,8-15H2,1-7H3,(H,28,33)/t18-,19-,20-,21+,22+,26-,27+/m0/s1
| StdInChIKey = WMPQMBUXZHMEFZ-YJPJVVPASA-N
}}

'''Turosteride''' ('''FCE-26,073''') is a [[binding selectivity|selective]] [[enzyme inhibitor|inhibitor]] of the [[enzyme]] [[5-alpha-reductase|5α-reductase]] which was under investigation by [[GlaxoSmithKline]] for the treatment of [[benign prostatic hyperplasia]] (BPH), but was never marketed.<ref name="isbn0-412-46630-9">{{cite book | author = David J. Triggle | title = Dictionary of Pharmacological Agents | publisher = Chapman & Hall/CRC | location = Boca Raton | year = 1996 | pages = | isbn = 0-412-46630-9 | oclc = | doi = | url = https://books.google.com/books?id=Z_mfTTIApVEC&printsec=frontcover#v=onepage&q&f=false}}</ref><ref name="pmid8240976">{{cite journal |vauthors=di Salle E, Giudici D, Briatico G, Ornati G, Panzeri A | title = Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat | journal = The Journal of Steroid Biochemistry and Molecular Biology | volume = 46 | issue = 5 | pages = 549–55 |date=November 1993 | pmid = 8240976 | doi = 10.1016/0960-0760(93)90181-U | url = }}</ref><ref name="pmid8142301">{{cite journal |vauthors=Di Salle E, Briatico G, Giudici D, Ornati G, Panzeri A | title = Endocrine properties of the testosterone 5 alpha-reductase inhibitor turosteride (FCE 26073) | journal = The Journal of Steroid Biochemistry and Molecular Biology | volume = 48 | issue = 2-3 | pages = 241–8 |date=February 1994 | pmid = 8142301 | doi = 10.1016/0960-0760(94)90151-1| url = http://linkinghub.elsevier.com/retrieve/pii/0960-0760(94)90151-1}}</ref> Similarly to [[finasteride]], turosteride is selective for the [[SRD5A2|type II]] [[isoform]] of 5α-redcutase, with about 15-fold selectivity for it over [[SRD5A1|type I]] isoform of the enzyme.<ref name="pmid7577710">{{cite journal |vauthors=Iehlé C, Délos S, Guirou O, Tate R, Raynaud JP, Martin PM | title = Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors | journal = The Journal of Steroid Biochemistry and Molecular Biology | volume = 54 | issue = 5-6 | pages = 273–9 |date=September 1995 | pmid = 7577710 | doi = 10.1016/0960-0760(95)00134-L| url = }}</ref><ref name="pmid17326010">{{cite journal |vauthors=Seiffert K, Seltmann H, Fritsch M, Zouboulis CC | title = Inhibition of 5alpha-reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro | journal = Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme | volume = 39 | issue = 2 | pages = 141–8 |date=February 2007 | pmid = 17326010 | doi = 10.1055/s-2007-961814 | url = http://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-961814}}</ref> In animal studies it has been shown to inhibit [[prostate]] size and retard [[tumor]] [[Cell growth|growth]].<ref name="pmid8240976"/><ref name="pmid8142301"/><ref name="pmid9051146">{{cite journal |vauthors=Zaccheo T, Giudici D, di Salle E | title = Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma | journal = The Prostate | volume = 30 | issue = 2 | pages = 85–91 |date=February 1997 | pmid = 9051146 | doi = 10.1002/(SICI)1097-0045(19970201)30:2<85::AID-PROS3>3.0.CO;2-J}}</ref><ref name="pmid9609545">{{cite journal |vauthors=Zaccheo T, Giudici D, di Salle E | title = Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats | journal = The Prostate | volume = 35 | issue = 4 | pages = 237–42 |date=June 1998 | pmid = 9609545 | doi = 10.1002/(SICI)1097-0045(19980601)35:4<237::AID-PROS1>3.0.CO;2-D}}</ref> It may also be useful for the treatment of [[acne]] and [[hair loss]].<ref name="isbn0-8247-2971-4">{{cite book |author1=Rawlings, Anthony V. |author2=Webster, Guy F. | title = Acne and its therapy | publisher = Informa Healthcare USA | location = New York | year = 2007 | pages = | isbn = 0-8247-2971-4 | oclc = | doi = | accessdate = }}</ref>

== See also ==
* [[5α-Reductase inhibitor]]
* [[FCE 28,260]]

== References ==
{{Reflist}}

{{Drugs used in benign prostatic hypertrophy}}
{{Other dermatological preparations}}
{{Androgenics}}

[[Category:5α-Reductase inhibitors]]
[[Category:Lactams]]
[[Category:Ureas]]
[[Category:Abandoned drugs]]